Eli Lilly Gets FDA Letter About Eczema Drug Concerns. The Stock Shrugs

The U.S. Food and Drug Administration sent Eli Lilly a Complete Response Letter (CLA) citing concerns regarding its treatment for moderate-to-sev...#elililly
Source: Reuters: Health - Category: Consumer Health News Source Type: news